DBF4 and cancer: Compounds AGR 1.230, AGR 1.121 and JAR 3.29 have shown to be able to inhibit CDC7 in a cellular model in the same way as clofoctol does, corroborating the possibility to modulate allosterically CDC7 by interrupting the protein-protein interaction with DBF4 motif C. These compounds may represent new potent pharmacological tools for different therapeutic studies where the activity of CDC7 is involved, mainly in cancer and TDP-43-proteinopathies such as ALS.